|
|
"Comparative gene resequencing in mouse cancer models"
|
5K08CA160658-03
|
$180,360
|
$90,180
|
McFadden, David
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
(PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancer
|
1R01CA180277-01
|
$275,552
|
$275,552
|
Li, Xin
|
NEW YORK UNIVERSITY
|
|
|
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
|
1R01CA180070-01
|
$377,488
|
$377,488
|
HEBER-KATZ, ELLEN S.
|
WISTAR INSTITUTE
|
|
|
(PQB6) Accurate Comparative Genome-wide Analysis of Primary Tumors and Metastases
|
1R21CA180016-01
|
$206,190
|
$206,190
|
Wotton, David
|
UNIVERSITY OF VIRGINIA
|
|
|
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer
|
1R01CA179991-01
|
$336,150
|
$336,150
|
IACOBUZIO-DONAHUE, CHRISTINE
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
|
1R01CA180149-01
|
$590,138
|
$590,138
|
AGUS, DAVID
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
(PQC4) Fate of cells disseminating from human breast cancer xenografts
|
1R01CA180039-01
|
$325,775
|
$325,775
|
WERB, ZENA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist
|
1R21CA179970-01
|
$200,970
|
$200,970
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
|
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer
|
1R21CA180145-01
|
$208,800
|
$104,400
|
Ozpolat, Bulent
|
UT MD ANDERSON CANCER CTR
|
|
|
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTS
|
1R01CA180061-01
|
$460,025
|
$460,025
|
Woodward, Wendy
|
UT MD ANDERSON CANCER CTR
|
|
|
18F-Fluorocholine to distinguish necrosis from recurrence in brain metastases
|
1R21CA170289-01A1
|
$366,860
|
$366,860
|
Beal, Kathryn
|
SLOAN-KETTERING INST CAN RES
|
|
|
2013 Gordon Research Conference on Hormone-Dependent Cancers: Development and Pro
|
1R13CA177078-01A1
|
$5,500
|
$2,750
|
Knudsen, Karen
|
GORDON RESEARCH CONFERENCES
|
|
|
2013 Matrix Metalloproteinase Gordon Research Conference and Gordon Research Semi
|
1R13CA176706-01
|
$3,000
|
$3,000
|
APTE, SUNEEL
|
GORDON RESEARCH CONFERENCES
|
|
|
2013, 2014 and 2015 Mammary Gland Biology Gordon Research Conference & Gordon Res
|
1R13CA177033-01
|
$5,000
|
$2,500
|
WOOD, TERESA
|
GORDON RESEARCH CONFERENCES
|
|
|
27-hydroxycholesterol as a link between obesity and breast cancer pathogenesis
|
1K99CA172357-01
|
$94,829
|
$94,829
|
NELSON, ERIK
|
DUKE UNIVERSITY
|
|
|
3D-Adhesion Stromagenesis in Cancer Permissiveness
|
5R01CA113451-07
|
$231,352
|
$231,352
|
CUKIERMAN, EDNA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
|
2R44CA132257-03
|
$638,567
|
$638,567
|
MORGAN, Lee
|
DEKK-TEC, INC.
|
|
|
4D Microfluidic Platforms for Targeting Breast Cancer:Lymphatic Interactions
|
1R21CA175931-01
|
$198,360
|
$198,360
|
SLOANE, BONNIE
|
WAYNE STATE UNIVERSITY
|
|
|
A 3-D in vitro platform of tumor metastasis (PQ24)
|
5R01CA170879-02
|
$318,879
|
$318,879
|
GEORGE, STEVEN
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
|
A Droplet-Based System for Capture, Manipulation, and Biochemical Profiling of Ra
|
1R21CA177447-01
|
$266,430
|
$266,430
|
JEFFREY, STEFANIE
|
STANFORD UNIVERSITY
|
|
|
A Genetic Screen for HCC Genes
|
5R01CA132962-04
|
$284,744
|
$284,744
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA
|
|
|
A High-Throughput Model for Human Melanoma
|
3R01CA121118-05S1
|
$59,552
|
$59,552
|
Holmen, Sheri
|
UNIVERSITY OF UTAH
|
|
|
A membrane-based immunotherapy for triple negative breast cancer
|
1R43CA176920-01
|
$144,759
|
$72,380
|
PACK, CHRISTOPHER
|
METACLIPSE THERAPEUTICS CORPORATION
|
|
|
A Microchip with Thermally Responsive Polymers for Capture and Recovery of CTCs
|
1R43CA180482-01
|
$200,465
|
$100,233
|
Garcia, Mitch
|
CYTOLUMINA TECHNOLOGIES CORPORATION, INC
|
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$101,345
|
$101,345
|
Kelly, Kathleen
|
CCR (NCI)
|
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
1U01CA166894-01A1
|
$369,879
|
$184,940
|
SUN, ZIJIE
|
STANFORD UNIVERSITY
|
|
|
A new radiopharmaceutical for the treatment of metastatic bone cancer
|
2R44CA150601-02A1
|
$694,709
|
$694,709
|
Simon, Jaime
|
ISOTHERAPEUTICS GROUP, LLC
|
|
|
A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer
|
5R01CA166376-02
|
$363,372
|
$363,372
|
Nguyen, Don
|
YALE UNIVERSITY
|
|
|
A novel murine model for metastatic islet cell pancreas cancer
|
5R21CA164795-02
|
$188,490
|
$188,490
|
GROSS, KENNETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
A novel photopatterning-based paradigm for the study of 3D tumor infiltration
|
1F32CA174361-01
|
$47,114
|
$47,114
|
Rape, Andrew
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
|
A Novel Plasminogen Receptor in Breast Cancer
|
5R01CA166473-02
|
$377,600
|
$377,600
|
MUELLER, BARBARA
|
TORREY PINES INST FOR MOLECULAR STUDIES
|
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$352,646
|
$246,852
|
Merlino, Glenn
|
CCR (NCI)
|
|
|
A NOVEL STRATEGY FOR THE TREATMENT OF MELANOMA
|
1R03CA175660-01
|
$66,120
|
$66,120
|
Xu, Mai
|
WASHINGTON UNIVERSITY
|
|
|
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer
|
5R01CA150182-03
|
$274,795
|
$274,795
|
AHMED, KHALIL
|
UNIVERSITY OF MINNESOTA
|
|
|
A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer
|
2R44CA139644-02A1
|
$484,215
|
$484,215
|
Hill, Samuel
|
ROGERS SCIENCES, INC.
|
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-25
|
$234,605
|
$58,651
|
Lozano, Guillermina
|
UT MD ANDERSON CANCER CTR
|
|
|
A research and training program for junior clinicians in treating metastatic mela
|
1K24CA172123-01A1
|
$156,084
|
$156,084
|
Kluger, Harriet
|
YALE UNIVERSITY
|
|
|
A role for c-Abl/Arg in melanoma progression
|
5R01CA166499-02
|
$294,962
|
$294,962
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
3R41CA174031-01S1
|
$147,010
|
$147,010
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma
|
1R41CA174008-01A1
|
$232,852
|
$232,852
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
A stem cell strategy to induce tumor stasis and inhibit metastasis of breast canc
|
1R01CA172480-01A1
|
$382,384
|
$382,384
|
Wang, Jianjun
|
WAYNE STATE UNIVERSITY
|
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
5U01CA084244-15
|
$699,208
|
$69,921
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
A VASCULARIZED MODELOF HUMAN BRAIN METASTASIS FOR SCREENING OF ANTI-CANCER DRUGS
|
N43CO130027-000
|
$299,986
|
$299,986
|
NEUMANN, THOMAS
|
NORTIS, INC.
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-37S2
|
$12,499
|
$1,500
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-37
|
$7,216,850
|
$866,022
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
|
5R01CA135328-04
|
$304,764
|
$304,764
|
Mahajan, Nupam
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
ACTIVIN SIGNALING AND REGULATION IN THE COLON
|
5R01CA141057-04
|
$259,676
|
$129,838
|
JUNG, BARBARA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
|
ADAM17 in pancreatic cancer and pancreatitis
|
5R01CA159222-03
|
$366,727
|
$366,727
|
CRAWFORD, HOWARD
|
MAYO CLINIC JACKSONVILLE
|
|
|
Adenosine in Tumor-Host Interaction
|
5R01CA138923-04
|
$332,045
|
$83,011
|
FEOKTISTOV, IGOR
|
VANDERBILT UNIVERSITY MED CTR
|
|
|
Adhesive regulation during cell migration
|
5R01CA085862-14
|
$261,562
|
$261,562
|
HUTTENLOCHER, ANNA
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Total relevant funding to Metastasis for this search: $362,002,333
|
